CanVasc关于阿伐可泮用于抗中性粒细胞胞浆抗体相关血管炎使用的共识推荐:2022年附录
加拿大血管炎研究网络(CanVasc)基于截至2022年9月的系统文献综述,采用EULAR分级和改良德尔菲法(共识≥80%)制定3条新推荐,聚焦阿伐可泮的治疗指征、疗程及糖皮质激素及时减量,为风湿科、肾科等专科医生提供指导。
要点
- 新增3条推荐,涉及阿伐可泮的治疗指征、疗程和糖皮质激素及时减量。
- 推荐基于截至2022年9月的系统文献综述和加拿大专家共识(≥80%)。
- 推荐分级采用EULAR分级标准。
核心结论
- 2022年附录推荐基于当前证据和加拿大专家共识,为风湿科、肾科等专科医生使用阿伐可泮提供指导。
研究设计与样本
- 加拿大血管炎研究网络(CanVasc)对截至2022年9月的文献进行系统综述,采用EULAR分级和改良德尔菲法(共识≥80%)制定推荐。
主要发现
- 共制定3条新推荐,聚焦阿伐可泮的治疗指征、疗程以及糖皮质激素的及时减量。
关键数值与推荐
- 3条新推荐涉及阿伐可泮的治疗指征、疗程和糖皮质激素及时减量,推荐分级采用EULAR分级标准。
临床怎么用
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In 2020, the Canadian Vasculitis Research Network (CanVasc) published their updated recommendations for the management of ANCA-associated vasculitides (AAV). The current addendum provides further recommendations regarding the use of avacopan in AAV based on a review of newly available evidence. METHODS: An updated systematic literature review on avacopan (formerly, CCX168) using Medline, Embase, and the Cochrane Library was performed for publications up to September 2022. New recommendations were developed and categorized according to the EULAR grading levels, as done for previous CanVasc recommendations. A modified Delphi procedure and videoconferences were used to reach ≥80% consensus on the inclusion, wording and grading of each recommendation. RESULTS: Three new recommendations were developed. They focus on avacopan therapy indication and duration, as well as timely glucocorticoid tapering. CONCLUSION: These 2022 addended recommendations provide rheumatologists, nephrologists and other specialists caring for patients with AAV with guidance for the use of avacopan, based on current evidence and consensus from Canadian experts.
引用
- Turgeon D, Bakowsky V, Baldwin C, et al. CanVasc consensus recommendations for the use of avacopan in antineutrophil cytoplasm antibody-associated vasculitis: 2022 addendum. Rheumatology (Oxford). 2023. PMID: 36805625. doi:10.1093/rheumatology/kead087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。